Eleven Biotherapeutics (EBIO) –
-
TransCode Therapeutics Announces Key Appointments
-
Form 8-K Sesen Bio, Inc. For: May 15
-
Form 8-K Sesen Bio, Inc. For: May 15
-
Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio
-
Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio
-
Form S-8 Eleven Biotherapeutics,
-
Form S-3/A Eleven Biotherapeutics,
-
Form 10-Q Eleven Biotherapeutics, For: Mar 31
-
Eleven Biotherapeutics Reports First Quarter Financial Results and Pipeline Updates
-
Form EFFECT Eleven Biotherapeutics,
-
Pre-Open Movers 05/10: (ARMO) (HEAR) (VTVT) Higher; (MDCA) (NUAN) (BKNG) Lower (more...)
-
UPDATE: Laidlaw Starts Eleven Biotherapeutics (EBIO) at Buy
-
Pre-Open Movers 05/07: (ATHN) (GPT) (NOG) Higher; (XRAY) (EBIO) (TSN) Lower (more...)
-
Eleven Biotherapeutics (EBIO) files to offer 7,968,128 shares of common stock issuable upon exercise of warrants.
-
Form S-3 Eleven Biotherapeutics,
-
Form DEF 14A Eleven Biotherapeutics, For: Jun 12
-
Form DEFA14A Eleven Biotherapeutics,
-
Eleven Biotherapeutics (EBIO) Says New Preclinical Data Highlighting its DeBouganin Program to be Presented at AACR
-
New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting
-
Form 4 Eleven Biotherapeutics, For: Apr 09 Filed by: Fitzgerald Richard F
-
Form 4 Eleven Biotherapeutics, For: Apr 09 Filed by: HURLY STEPHEN A
-
Form 8-K Eleven Biotherapeutics, For: Apr 04
-
Form 8-K Eleven Biotherapeutics, For: Apr 03
-
Form D Eleven Biotherapeutics,
-
Eleven Biotherapeutics Reports Fourth Quarter and Full-Year 2017 Operating Results and Vicinium Development Progress
-
Form SC 13G Eleven Biotherapeutics, Filed by: KINGDON CAPITAL MANAGEMENT, L.L.C.
-
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting
-
Form 10-K Eleven Biotherapeutics, For: Dec 31
-
Form 8-K Eleven Biotherapeutics, For: Mar 21
-
Form 8-K Eleven Biotherapeutics, For: Mar 21
-
Form 424B5 Eleven Biotherapeutics,
-
Form SC 13G Eleven Biotherapeutics, Filed by: SABBY MANAGEMENT, LLC
-
Eleven Biotherapeutics (EBIO) Prices $10M Offering of Common Stock, Warrants
-
Eleven Biotherapeutics Announces Pricing of $10.0 Million Offering Priced At-the-Market
-
UPDATE: H.C. Wainwright Starts Eleven Biotherapeutics (EBIO) at Buy
-
Form S-3 Eleven Biotherapeutics,
-
Form 4 Eleven Biotherapeutics, For: Mar 14 Filed by: HURLY STEPHEN A
-
Form 8-K Eleven Biotherapeutics, For: Mar 12
-
Eleven Biotherapeutics (EBIO) Reports Completed Enrollment in VISTA Phase 3 Registration Trial of Vicinium
-
Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer
-
Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference
-
Eleven Biotherapeutics to Present at 2018 BIO CEO & Investor Conference
-
Form 4 Eleven Biotherapeutics, For: Jan 23 Filed by: Fitzgerald Richard F
-
Form SC 13G/A Eleven Biotherapeutics, Filed by: Empery Asset Management, LP
-
Form 8-K Eleven Biotherapeutics, For: Jan 23
-
Eleven Biotherapeutics (EBIO) Names Richard Fitzgerald as CFO
-
Eleven Biotherapeutics Appoints Richard Fitzgerald as Chief Financial Officer
-
Form 4 Eleven Biotherapeutics, For: Jan 18 Filed by: HURLY STEPHEN A
-
Eleven Biotherapeutics to Present at Biotech Showcase 2018
-
Form 8-K Eleven Biotherapeutics, For: Dec 13
Back to EBIO Stock Lookup